INTERFERON BETA-1A

Summary

Interferon Beta-1A (CHEMBL1201562) is an approved protein (ATC L03AB07); indicated across 16 conditions including neoplasm and multiple sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AB07
• Indications: 16 conditions
• Clinical trials: 79

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201562
Name	INTERFERON BETA-1A
Type	Protein
Max phase	4
ATC	L03AB07

Also known as: Avonex, Cinnovex, Interferon beta-1a, Interferon beta-1a (avonex), Interferon beta-1a (rebif), Neoferon, Rebif, SNG-001, Sng001, SNG001, INTERFERON BETA-1A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
multiple sclerosis	4	MONDO:0005301	MONDO:0005301
relapsing-remitting multiple sclerosis	3	MONDO:0005314	EFO:0003929
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
adult acute respiratory distress syndrome	3	MONDO:0100130	MONDO:0100130
pneumonia	3	MONDO:0005249	EFO:0003106
influenza	3	MONDO:0005812	EFO:0007328
ulcerative colitis	2	MONDO:0005101	EFO:0000729
Crohn disease	2	MONDO:0005011	EFO:0000384
chronic inflammatory demyelinating polyradiculoneuropathy	2	MONDO:0006702	EFO:1000868
multiple organ dysfunction syndrome	2	MONDO:0043726	EFO:1001373
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
asthma	2	MONDO:0004979	MONDO:0004979
stroke disorder	1	MONDO:0005098	EFO:0000712

Clinical trials

Total trials: 79.

Phase distribution

Phase	Trials
PHASE2	18
PHASE3	17
PHASE4	16
Not specified	15
PHASE1	11
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00101959	PHASE4	WITHDRAWN	Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
NCT00146068	PHASE4	COMPLETED	EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
NCT00202995	PHASE4	TERMINATED	Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
NCT00317941	PHASE4	COMPLETED	Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
NCT00534261	PHASE4	COMPLETED	Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
NCT00574041	PHASE4	TERMINATED	How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
NCT00771043	PHASE4	WITHDRAWN	A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
NCT00913666	PHASE4	COMPLETED	Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
NCT00915460	PHASE4	COMPLETED	Open-Label Safety Extension Study of Avonex
NCT01085318	PHASE4	COMPLETED	Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
NCT01142466	PHASE4	COMPLETED	A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
NCT01201343	PHASE4	COMPLETED	Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
NCT02019550	PHASE4	COMPLETED	Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
NCT02254304	PHASE4	COMPLETED	Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
NCT03177083	PHASE4	COMPLETED	Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
NCT04350671	PHASE4	UNKNOWN	Interferon Beta 1a in Hospitalized COVID-19 Patients
NCT01892722	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT00530348	PHASE3	COMPLETED	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00548405	PHASE3	COMPLETED	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
NCT00915577	PHASE3	COMPLETED	Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
NCT01058005	PHASE3	TERMINATED	Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
NCT01064401	PHASE3	COMPLETED	Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
NCT01181115	PHASE3	COMPLETED	Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
NCT01247324	PHASE3	COMPLETED	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT01412333	PHASE3	COMPLETED	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
NCT02047734	PHASE3	COMPLETED	Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
NCT02294058	PHASE3	COMPLETED	Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
NCT02622724	PHASE3	TERMINATED	Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
NCT04315948	PHASE3	COMPLETED	Trial of Treatments for COVID-19 in Hospitalized Adults
NCT04492475	PHASE3	COMPLETED	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
NCT04518410	PHASE2/PHASE3	COMPLETED	ACTIV-2: A Study for Outpatients With COVID-19
NCT04647669	PHASE3	UNKNOWN	World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
NCT04732949	PHASE3	COMPLETED	Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
NCT06019130	PHASE2	RECRUITING	Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
NCT06510426	PHASE2	RECRUITING	Early Interferon-beta Treatment for West-Nile Virus Infection
NCT06999603	PHASE2	RECRUITING	Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
NCT00048347	PHASE2	COMPLETED	Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
NCT00050778	PHASE2	COMPLETED	A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
NCT00099489	PHASE2	COMPLETED	Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).